Who owns Kalvista Pharmaceuticals?
- Ticker: KALV
- CUSIP Number: 483497103
Tip: Access positions for across all investors
Analyze quarterly positions in Kalvista Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Kalvista Pharmaceuticals stock
Who bought or sold Kalvista Pharmaceuticals this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| VR Adviser | 4.1M | $50M | 40% | Dec 2023 |
|
| Frazier Life Sciences Management | 3.6M | $44M | 12% | Dec 2023 |
|
| Tang Capital Management | 3.4M | $42M | 0% | Dec 2023 |
|
| Vanguard Group | 1.8M | $22M | 3% | Dec 2023 |
|
| Boxer Capital | 1.7M | $20M | 0% | Dec 2023 |
|
| Caption Management | 887k | $11M | 0% | Dec 2023 |
|
| Citadel Advisors | 865k | $11M | -8% | Dec 2023 |
|
| Dimensional Fund Advisors | 717k | $8.8M | 23% | Dec 2023 |
|
| DAFNA Capital Management | 601k | $7.4M | -1% | Dec 2023 |
|
| Goldman Sachs Group | 331k | $4.1M | 58% | Dec 2023 |
|
| Rosalind Advisors | 300k | $3.7M | 100% | Dec 2023 |
|
| Citigroup | 282k | $3.5M | 2% | Dec 2023 |
|
| Two Sigma Advisers | 203k | $2.5M | 16% | Dec 2023 |
|
| Two Sigma Investments | 166k | $2.0M | 60% | Dec 2023 |
|
| Opaleye Management | 150k | $1.8M | -70% | Dec 2023 |
|
| SG Americas Securities | 138k | $1.7M | 5% | Dec 2023 |
|
| AlphaCentric Advisors | 130k | $1.5M | -4% | Mar 2024 |
|
| Connor, Clark & Lunn Investment Management | 111k | $1.4M | 6% | Dec 2023 |
|
| Bank of New York Mellon | 101k | $1.2M | 19% | Dec 2023 |
|
| Walleye Trading Advisors | 98k | $1.2M | 68% | Dec 2023 |
|
| D. E. Shaw & Co | 89k | $1.1M | -23% | Dec 2023 |
|
| Charles Schwab Investment Management | 81k | $986k | 23% | Dec 2023 |
|
| Healthcare Of Ontario Pension Plan Trust Fund | 52k | $631k | -63% | Dec 2023 |
|
| State of Wisconsin Investment Board | 51k | $626k | -31% | Dec 2023 |
|
| Millennium Management | 50k | $613k | 100% | Dec 2023 |
|
| Rhumbline Advisers | 45k | $556k | 8% | Dec 2023 |
|
| Barclays | 43k | $521k | 909% | Dec 2023 |
|
| Jane Street | 38k | $460k | 15% | Dec 2023 |
|
| Bank of America Corporation | 33k | $399k | 45% | Dec 2023 |
|
| Alliancebernstein | 30k | $368k | -7% | Dec 2023 |
|
| UBS Group | 27k | $331k | 22% | Dec 2023 |
|
| Jpmorgan Chase & Co | 27k | $328k | -90% | Dec 2023 |
|
| LMR Partners | 25k | $306k | 0% | Dec 2023 |
|
| Legato Capital Management | 24k | $281k | 100% | Mar 2024 |
|
| T. Rowe Price Associates | 21k | $260k | 12% | Dec 2023 |
|
| Walleye Trading | 20k | $244k | 100% | Dec 2023 |
|
| MetLife Investment Advisors | 17k | $206k | 34% | Dec 2023 |
|
| American International | 15k | $189k | 25% | Dec 2023 |
|
| Cubist Systematic Strategies | 15k | $181k | 100% | Dec 2023 |
|
| Balyasny Asset Management | 12k | $146k | 12% | Dec 2023 |
|
| Deutsche Bank Aktiengesellschaft | 12k | $141k | -3% | Dec 2023 |
|
| Principal Financial Group | 12k | $141k | 2% | Dec 2023 |
|
| Wells Fargo & Company | 11k | $133k | 46% | Dec 2023 |
|
| Mirae Asset Global Investments | 10k | $126k | 100% | Dec 2023 |
|
| New York State Common Retirement Fund | 9.9k | $121k | 0% | Dec 2023 |
|
| Royal Bank of Canada | 9.8k | $121k | 132% | Dec 2023 |
|
| Bnp Paribas Arbitrage, Snc | 9.3k | $114k | 151% | Dec 2023 |
|
| AJOVista | 4.9k | $60k | 100% | Dec 2023 |
|
| NISA Investment Advisors | 4.3k | $53k | 0% | Dec 2023 |
|
| China Universal Asset Management | 4.0k | $49k | 100% | Dec 2023 |
|
| Legal & General Group | 2.6k | $32k | 33% | Dec 2023 |
|
| Summit Investment Advisors | 2.5k | $30k | 0% | Dec 2023 |
|
| Metropolitan Life Insurance Company | 1.8k | $22k | 35% | Dec 2023 |
|
| Amalgamated Bank | 1.1k | $13k | -49% | Mar 2024 |
|
| Signature | 198.00 | $2.4k | 144% | Dec 2023 |
|
| Red Tortoise | 187.00 | $2.2k | 0% | Mar 2024 |
|
| Garner Asset Management Corp | 135.00 | $2.0k | 100% | Dec 2023 |
|
| GAMMA Investing | 16.00 | $190.000000 | 0% | Mar 2024 |
|
| Pnc Financial Services | 5.00 | $61.000000 | 100% | Dec 2023 |
|
| Fortitude Family Office | 3.00 | $36.000000 | 0% | Mar 2024 |
|
Who sold out of Kalvista Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Logos Global Management | Sep 2023 | 900k | $8.7M |
| Vivo Capital | Dec 2023 | 856k | $11M |
| Ikarian Capital | Sep 2023 | 143k | $1.4M |
| Marshall Wace | Sep 2023 | 52k | $496k |
| PDT Partners | Sep 2023 | 38k | $364k |
| ALPS Advisors | Sep 2023 | 25k | $244k |
| Algert Coldiron Investors | Sep 2023 | 23k | $224k |
| PanAgora Asset Management | Sep 2023 | 23k | $221k |
| Bank Of Montreal | Sep 2023 | 11k | $110k |
| OTR - Nominee Name for The State Teachers Retirement Board of Ohio | Sep 2023 | 11k | $104k |
| Jump Financial | Sep 2023 | 10k | $98k |
| Simplex Trading | Sep 2023 | 8.8k | $84k |
| Hanson McClain Advisors | Sep 2023 | 27.00 | $261.000900 |
| Newbridge Financial Services Group | Sep 2023 | 25.00 | $241.000000 |